

Mutations in *DMRT3* affect locomotion in horses and spinal circuit function in mice

Lisa S. Andersson^{1*}, Martin Larhammar^{2*}, Fatima Memić^{2*}, Hanna Wootz^{2*}, Doreen Schwochow¹, Carl-Johan Rubin³, Kalicharan Patra², Thorvaldur Arnason⁴, Lisbeth Wellbring¹, Göran Hjälms³, Freyja Imsland³, Jessica L. Petersen⁵, Molly E. McCue⁵, James R. Mickelson⁵, Gus Cothran⁶, Nadav Ahituv^{7,8}, Lars Roepstorff⁹, Sofia Mikko¹, Anna Vallstedt², Gabriella Lindgren¹, Leif Andersson^{1,3*} & Klas Kullander^{2*}

Locomotion in mammals relies on a central pattern-generating circuitry of spinal interneurons established during development that coordinates limb movement¹. These networks produce left-right alternation of limbs as well as coordinated activation of flexor and extensor muscles². Here we show that a premature stop codon in the *DMRT3* gene has a major effect on the pattern of locomotion in horses. The mutation is permissive for the ability to perform alternate gaits and has a favourable effect on harness racing performance. Examination of wild-type and *Dmrt3*-null mice demonstrates that *Dmrt3* is expressed in the dl6 subdivision of spinal cord neurons, takes part in neuronal specification within this subdivision, and is critical for the normal development of a coordinated locomotor network controlling limb movements. Our discovery positions *Dmrt3* in a pivotal role for configuring the spinal circuits controlling stride in vertebrates. The *DMRT3* mutation has had a major effect on the diversification of the domestic horse, as the altered gait characteristics of a number of breeds apparently require this mutation.

Horses show considerable variation in the pattern of locomotion. The three naturally occurring gaits in all equids are, in order of increasing speed, walk, trot and canter/gallop. Some horses can use alternate gaits, typically at intermediate speed, and 'gaitedness' is a trait upon which many specialized breeds have been developed. Based on variation in footfall pattern, timing and cadence, these alternate gaits can be generally divided into four categories: pace, regular rhythm ambling, lateral ambling and diagonal ambling (Supplementary Notes and Supplementary Table 1). Pace is a two-beat gait in which the horse moves the two legs on the same side of the body in a synchronized, lateral movement (Fig. 1a) in contrast to the trot, where the diagonal front and hind legs move forward and backward together (Fig. 1b). Ambling gaits are four-beat gaits in which footfall pattern, foot placement and timing are often unique to specific breeds (Supplementary Notes and Supplementary Table 1). Tölt is a regular ambling gait characteristic of the Icelandic horse. Many Icelandic horses also have the ability to pace and test scores for pace show a bimodal distribution (Fig. 1c) and high heritability, in the range 0.60–0.73 (ref. 3).

A genome-wide association analysis using 30 Icelandic horses classified as four-gaited (walk, tölt, trot and gallop) and 40 classified as five-gaited (walk, tölt, trot, gallop and pace) revealed a highly significant association between the ability to pace and a single nucleotide polymorphism (SNP; BIEC2_620109) at nucleotide position 22967656 on chromosome 23 (Fig. 1d). The two flanking markers showed only weak association to the pacing phenotype, indicating that the mutation(s) underlying the association is located within the 684-kilobases

interval chr23:22628976–23315071. We resequenced selected regions of the 684-kb interval in a panel of four- and five-gaited Icelandic horses. The five-gaited horses were all homozygous for a minimal 438-kb haplotype (chr23:22877015–23315071), that was inferred to be identical-by-descent (IBD; Supplementary Table 2). This region contains only three genes encoding different isoforms of the doublesex and mab-3 related transcription factors, *DMRT1–3* (Fig. 1e). The *DMRT* family of transcription factors carry a DM (dsx and mab-3) DNA-binding domain, conferring sequence-specific DNA binding distinct from a classical zinc-finger⁴.

We performed whole-genome resequencing of one four-gaited and one five-gaited Icelandic horse, homozygous for opposite alleles at the SNP associated with the ability to pace. Average sequence coverage of 30× was obtained and polymorphisms identified in the critical 438-kb interval were compiled (Supplementary Table 3). Homozygosity mapping using the sequenced five-gaited horse confirmed an IBD region of about 438 kb. In this interval, we identified 65 sequence differences (60 SNPs and five small insertions/deletions) unique to the five-gaited horse when comparing data for the two horses and the reference genome (Supplementary Table 4); no structural rearrangements were detected. We found five intronic or intragenic SNPs at sites showing some degree of evolutionary conservation, and a single base change at nucleotide position chr23:22999655 causing a premature stop at codon 301 in *DMRT3* (*DMRT3_Ser301STOP*; Fig. 1f). The allele is expected to encode a truncated protein lacking 174 amino acid residues of the full-length protein (Fig. 1g), of which 161 (92.5%) are identical between human and horse *Dmrt3*. *DMRT3_Ser301STOP* was evaluated as the candidate causative mutation.

We genotyped 352 additional Icelandic horses and found that all but one of the five-gaited horses were homozygous A/A for the *DMRT3* nonsense mutation (Table 1); further investigation of competition records revealed that this single discordant horse was most likely phenotypically misclassified. In contrast, only 31% of the four-gaited horses were homozygous A/A ($P = 2.4 \times 10^{-14}$). Thus, homozygosity for the *DMRT3* nonsense mutation is required for the ability to pace in this breed. The observation that a considerable number of homozygous mutant horses are considered four-gaited may reflect phenotype misclassifications, but more likely incomplete penetrance due to other genetic factors, maturity and environmental effects, in particular training.

The *DMRT3* genotype distribution across breeds was markedly dichotomous, with the mutation occurring at high frequency in all gaited breeds, whereas all tested non-gaited horses were homozygous wild type (Table 1), with the exception of horses used for harness

¹Department of Animal Breeding and Genetics, Swedish University of Agricultural Sciences, SE-75124 Uppsala, Sweden. ²Department of Neuroscience, Uppsala University, SE-75124 Uppsala, Sweden.

³Department of Medical Biochemistry and Microbiology, Uppsala University, SE-75123 Uppsala, Sweden. ⁴Faculty of Land and Animal Resources, The Agricultural University of Iceland, IS-311 Borgarnes, Iceland.

⁵College of Veterinary Medicine, University of Minnesota, St Paul, Minnesota 55108, USA. ⁶Department of Veterinary Integrative Biosciences, College of Veterinary Medicine and Biomedical Sciences, Texas A&M University, College Station, Texas 77483, USA. ⁷Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California 94143, USA.

⁸Institute for Human Genetics, University of California San Francisco, San Francisco, California 94143, USA. ⁹Unit of Equine Studies, Swedish University of Agricultural Sciences, Uppsala, SE-75007 Sweden.

*These authors contributed equally to this work.




Figure 1 | Identification of a *DMRT3* mutation in horses. **a**, A pacing Icelandic horse, fore- and hindlegs on the same side of the body are synchronized. **b**, A trotting Icelandic horse, the diagonal fore- and hindlegs are synchronized. **c**, Distribution of breeding evaluation test scores for pace and trot in Icelandic horses. Score 5.0 indicates 'gait not shown'. **d**, Genome-wide association analysis revealed a highly significant association between the ability to pace and SNP BIEC2_620109 on chromosome 23 ($P_{\text{raw}} = 1.7 \times 10^{-9}$, corrected empirical P -value (EMP2) = 2.0×10^{-4} , genome-wide significance).

e, The 684 kb genomic interval associated with the *Gait* locus; the minimum *Gait* IBD region (438 kb) is shaded. **f**, Partial amino acid alignment of the predicted *Dmrt3* protein in wild-type (WT) and mutant (MUT) horses and in other vertebrates. Horse nonsense mutation (red asterisk), sequence identities (dashes), insertions/deletions (dots). **g**, Schematics of wild-type and mutant *Dmrt3*. DM, zinc-finger like DNA binding module; DMA, protein domain of unknown function present in *DMRT* proteins.

racing (see below). Nearly all individuals from other gaited breeds were homozygous mutant, regardless of whether their four-beat alternate gait is characterized by lateral or diagonal couplets (Supplementary Table 1). Thus, the *DMRT3* mutation is permissive for the ability to perform alternate gaits, which can be either pace or four-beat ambling gaits. Although this mutation must be advantageous for gaited horses,

it may be disadvantageous for others. In fact, Icelandic horse homozygous mutants had inferior scores for gallop and trot (Supplementary Table 5). Thus, there may be selection against the mutation in non-gaited horses bred for dressage, show jumping or high-speed gallop.

We found a high frequency of the *DMRT3* mutation in horses bred for harness racing (Table 1). These horses have the ability to trot or pace at high speed without breaking into a gallop, the natural gait at high speed for horses. The American Standardbred was established in the 19th century and bred for harness racing. Competitions are held separately in trot or pace and assortative mating based on preferred gait has subdivided the breed into two populations, pacers and trotters. In contrast to the pattern in Icelandic horses, where homozygosity for *DMRT3_Ser301STOP* was associated with the ability to pace, both Standardbred pacers and trotters are homozygous for the mutation. Thus, the mutation may promote the ability to trot or pace at high speed and genetic modifiers determine the gait to which the horse is best suited.

The Swedish Standardbred is largely developed from the American Standardbred but is not completely fixed for the *DMRT3* mutation, probably owing to the import of French trotters, a breed with a fairly high frequency of the wild-type allele (Table 1). The segregation of the two alleles in the Swedish Standardbred provided an opportunity to examine the effect of the mutation on racing performance. The *DMRT3* mutation was associated with superior breeding values (BV) for racing performance ($BV_{\text{CA}} = 95.7 \pm 1.7$, $n = 17$; $BV_{\text{AA}} = 109.0 \pm 0.8$, $n = 206$; $P < 0.0001$) and increased earned prize money ($X_{\text{CA}} = 48,000 \pm \text{US\$}35,000$, $n = 17$; $X_{\text{AA}} = 161,000 \pm \text{US\$}24,000$, $n = 206$; $P_{\text{one-sided}} = 0.007$). We also genotyped 61 horses from one racing camp in a blind test; two of these had major difficulties in sustaining trot at high speed (Supplementary Fig. 1a, b and Supplementary Movie 1) and were heterozygous C/A, whereas all others were homozygous A/A ($P = 0.0005$).

Whereas the horse discovery demonstrates that *DMRT3* has an effect on gait coordination, studies of its possible role in locomotor

Table 1 | Allele frequency of the *DMRT3* nonsense mutation among horse populations

Breed	<i>n</i>	<i>p</i> (A)
Icelandic horses*		
Four-gaited†	124	0.65
Five-gaited	66	0.99
Random sample	162	0.89
Other gaited horses		
Kentucky mountain saddle horse	22	0.95
Missouri fox trotter	40	1.00
Paso fino	45	1.00
Peruvian paso	19	1.00
Rocky mountain horse	17	1.00
Tennessee walking horse	33	0.98
Non-gaited horses		
Arabian horse	18	0.00
Gotland pony	28	0.00
North-Swedish draft horse	31	0.00
Przewalski's horse	6	0.00
Shetland pony	20	0.00
Swedish ardennes	22	0.00
Swedish warmblood	64	0.00
Thoroughbred	29	0.00
Horses bred for harness racing		
Standardbred, trotter (Sweden)	270	0.97
Standardbred, trotter (USA)	57	1.00
Standardbred, pacer (USA)	40	1.00
French trotter (France)	47	0.77

*These do not include the horses used in the initial genome-wide association and therefore provide a replication of the highly significant association.

†Thirty-eight of the 124 four-gaited horses were homozygous A/A.

n, number of horses; *p*(A)=allele frequency of the *DMRT3* nonsense mutation.

circuitry are more tractable in mice. We used *Dmrt3*-null mice⁵ (Supplementary Fig. 2) and evaluated locomotion performances. Motor coordination and balance were largely normal in *Dmrt3*^{-/-} mice (Supplementary Fig. 3a–c). In water, *Dmrt3*^{-/-} mice spent less time swimming and showed frequent twitching limb movements rarely observed in controls (Fig. 2a and Supplementary Movie 2). Next, mice were placed on a TreadScan apparatus, which performs an automated and unbiased analysis to collect multiple gait parameters (Supplementary Table 6). *Dmrt3*^{-/-} mice, but not control mice (wild-type littermates), had major difficulties running at higher velocities (Fig. 2b and Supplementary Movie 3). Gait analysis (Fig. 2c) revealed significantly increased stride length in all limbs of *Dmrt3*^{-/-} mice (Fig. 2d). Swing times (flexion) were increased in all limbs, whereas stance time (extension) was increased in forelimbs (Fig. 2e, f). Moreover, propulsion time increased in all limbs, whereas brake time was decreased in hindlimbs, indicating that *Dmrt3*^{-/-} mice may emphasize extension movements, resulting in a longer stride (Supplementary Table 6). Heterozygotes did not differ significantly from controls.

Development of weight-supported walking was similar in wild-type and *Dmrt3*^{-/-} mice (Supplementary Fig. 3d, e), whereas limb coordination in neonatal mice, scored during air-stepping, was markedly different (Fig. 2g). At postnatal (P) day 4, we observed similar numbers of alternating step movements in all wild-type limbs as well as in

Dmrt3^{-/-} mice forelimbs. However, alternating hindlimb movements were almost absent in *Dmrt3*^{-/-} mice (Fig. 2h), accompanied by increased uncoordinated step movements (Supplementary Fig. 3f). This early effect was emphasized by a similar phenotype at P1 (Supplementary Fig. 3g–i). Next, we analysed central pattern generator output in the isolated neonatal spinal cord using drug-induced fictive locomotion. Cords from wild-type mice generated a stable rhythm, whereas cords from *Dmrt3*^{-/-} mice had uncoordinated and irregular firing rhythms as well as increased burst and interburst durations (Fig. 2i–k). Moreover, the coefficient of variation, a normalized measure of variability, increased two- to threefold (Supplementary Fig. 4). We analysed the rhythm relationship between the left-right (l/r) and flexion-extension (f/e) outputs using a continuous wavelet transform that measures the coherence between the spinal ventral roots with high resolution^{6,7}. Wild-type and heterozygous mice had coherence frequencies around 0.4 Hz with clear coordinated left-right and flexion-extension alternation (coherence in wild-type l/r 95%, f/e 92%). In contrast, *Dmrt3*^{-/-} mice showed more variable and lower frequency values (≈ 0.1 Hz), and bursts were non-coherent between left-right and flexion-extension (Fig. 2l, m). The coherence values were lower (l/r 23%, f/e 25%) and significantly reduced compared to wild-types ($P = 0.01$, l/r; $P = 0.01$, f/e). The remaining coherent activity showed no clear direction towards synchrony or alternation (Supplementary Fig. 4). Excitation-inhibition balance can be influenced by the glycine




Figure 2 | Characterization of motor coordination in mice lacking *Dmrt3*.

a, *Dmrt3*^{-/-} mice showed decreased swimming duration ($P < 0.0001$), and an increase in twitching movements compared to control and *Dmrt3*^{+/-} ($P = 0.0002$; $n = 5$ control and *Dmrt3*^{-/-}, $n = 7$ *Dmrt3*^{+/-}). Time spent immobile was similar between genotypes ($P = 0.13$). **b**, Mice were tested for their ability to run (>5 step cycles) at different treadmill speeds (9, 15, 20, 25, 30 cm s^{-1}) ($n = 15$ trials per genotype, five animals). *Dmrt3*^{-/-} mice had difficulties at 20 cm s^{-1} ($P = 0.04$) with markedly reduced number of successful trials at 25 cm s^{-1} ($P = 0.006$) and 30 cm s^{-1} ($P < 0.0001$) compared to controls. **c**, Schematic drawing of the gait parameters analysed in treadmill locomotion. **d–f**, At 20 cm s^{-1} *Dmrt3*^{-/-} showed increased stride (**d**, forelimb: $P < 0.0001$, hindlimb: $P = 0.006$), hind limb stance (**e**, $P = 0.02$) and swing (**f**, forelimb: $P < 0.0001$, hindlimb: $P = 0.001$) time duration compared to

control ($n = 11$ –12 trials per genotype, five animals). **g**, Images of a P4 mouse airstepping. **h**, *Dmrt3*^{-/-} mice showed a decreased number of alternating hindlimb steps during airstepping ($P = 0.02$ compared to controls; $n = 4$ per genotype, except controls $n = 3$). Wild-type littermate controls (white), *Dmrt3*^{+/-} (grey), *Dmrt3*^{-/-} (black). Mean $\pm$ s.e.m. **i–m**, Fictive locomotion was recorded from ventral left (l) and right (r) lumbar (L) root 2 and 5 from neonatal spinal cords. **i, j**, Representative traces from control (**i**) and *Dmrt3*^{-/-} (**j**) spinal cords. Time scale 10 s. **k**, *Dmrt3*^{-/-} mice displayed increased burst and interburst durations compared to control animals, analysis made on L2s ($n = 6$ per genotype, $P = 0.02$, burst; $P = 0.001$, interburst). **l, m**, Coherence power spectra analysis of left/right (l/r) and flexor/extensor (f/e) recordings (colour-graded scale; $n = 3$ –5 per genotype). Time scale 100 s.

re-uptake inhibitor sarcosine⁸; however, the collapsed coordination observed here was unaffected by such treatment. Moreover, strychnine-induced synchronous bursting was similar between genotypes, indicating that excitatory cross coupling was present in *Dmrt3*^{-/-} mice (Supplementary Fig. 4).

Post-natally, *Dmrt3* messenger RNA was expressed in the ventral spinal cord at all levels, whereas prenatal expression was evident in more dorsally located cells, indicative of dorsoventral migration (Fig. 3a, b and Supplementary Fig. 5). Already at embryonic day (E) 12.5, *Dmrt3* cells were found in the medioventral domain, a pattern that persisted in adults. To pinpoint the origin of *Dmrt3* cells, we used markers for dorsal and ventral progenitors giving rise to different subclasses of interneurons⁹ (Fig. 3c). Immunostainings at E11.5 for *Dmrt3* and Pax7, a marker for the dorsal progenitor domain¹⁰, demonstrated that *Dmrt3* immunopositive (+) cells are generated near the ventral Pax7⁺ domain border (Fig. 3d). Moreover, *Dmrt3*⁺ cells were found within the Pax2 domain marking dl4, dl5 and V0d progenitors¹¹, while they were negative for *Evx1*, a post-mitotic marker for V0v interneurons¹². *Dmrt3* expression did not coincide with the dl5 marker *Lmx1b*¹³ whereas labelling with the dl4–6 postmitotic marker *Lbx1* (ref. 14) indicated that the *Dmrt3*⁺ population arise from the ventral-most *Lbx1* domain (Fig. 3d). These data indicate that *Dmrt3* marks a dl6 interneuron subpopulation, further confirmed by *in situ* hybridization analysis and additional markers (Supplementary Fig. 5). At E14.5, we found a partial overlap with *Wt1* (Fig. 3e), proposed to label the dl6 population¹⁵. *Dmrt3*⁺ interneurons in P11 spinal sections were positive for *Viaat* (also known as *Slc32a1*), marking inhibitory neurons, but negative for *Vglut2* (also known as *Slc17a6*), marking the majority of spinal excitatory neurons¹⁶ (Fig. 3f). Fluorescein-dextran retrograde tracings in E15 spinal cords¹⁷ revealed *Dmrt3*⁺ interneurons that extended projections ipsilaterally (22%) and contralaterally (39%). Contralateral fibres were not observed at E12.5, indicating that midline crossing occurs between E12.5 and E15.5 (Supplementary Fig. 6). Trans-synaptic pseudorabies-virus tracing in hindlimb muscles was used to examine whether *Dmrt3* interneurons contact motor neurons (Fig. 3g). Forty hours post-infection, we found virus⁺/*Dmrt3*⁺ cells both ipsi- and contralateral to the injected muscle, indicating direct connections to motor neurons¹⁸ and corroborating the presence of commissural fibres from *Dmrt3*⁺ cells (Fig. 3h). Although their character may change in the adult mouse, our developmental analysis suggests that *Dmrt3*-expressing cells originate from dl6 progenitors at around E11.5, develop into inhibitory interneurons with projecting axons ipsi- and contralateral, and make synaptic connections to motor neurons.

Because loss of *Dmrt3* may affect interneuron development in mice, we next analysed the dl6 population, and the flanking dl5 and V0d populations, by Pax2, *Brn3a* and *Lbx1* immunostainings. All three populations remained of similar sizes in wild-type and *Dmrt3*^{-/-} mice (Fig. 3i). In contrast, we found a 58% increase in the number of *Wt1*⁺ neurons in *Dmrt3*^{-/-} mice (Fig. 3j–l, $P < 0.0001$), suggesting a fate change within a specific subset of dl6 neurons. Moreover, retrograde tracing in E15 and P0 animals revealed significant decreases in commissural interneuron numbers in *Dmrt3*^{-/-} mice compared to wild-type at E15 ($P = 0.001$) and P0 ($P = 0.005$) (Supplementary Fig. 6). Thus, loss of *Dmrt3* resulted in an increased number of *Wt1*⁺ cells and fewer commissural interneurons, probably explained by an altered fate of the *Dmrt3*⁺ population. In general, loss of transcription factor expression within progenitor domains results in neuron specification defects, presumably by suppression of differentiation programs operating in adjacent domains^{15,19–21}. Our results suggest an early reprogramming of spinal interneurons; however, circuit reorganization, compensation issues and the direct role of *Dmrt3*⁺ interneurons require further investigation.

As the horse *DMRT3* mutation occurs in the last exon, the mRNA is not expected to be subject to nonsense-mediated RNA decay²² and the mutant allele is probably translated into a truncated form (Fig. 1g).




Figure 3 | Characterization of *Dmrt3*-expressing cells in the mouse spinal cord. **a**, *Dmrt3* mRNA expression pattern in adult spinal cord (P60). **b**, *Dmrt3* mRNA expression in a restricted population of neurons migrating ventrally in the developing spinal cord at E11.5. **c**, A schematic spinal cord cross-section showing progenitor and transcription factor domains. **d**, Double immunolabelling of *Dmrt3* and Pax7 shows that *Dmrt3*⁺ cells originate from the ventral-most part (bracket) of the dorsal domain (border indicated by line). *Dmrt3*⁺ cells overlap with the dl4/dl6/V0d marker Pax2, but not with the V0v/V0c/V0g marker *Evx1* or the dl5 marker *Lmx1b* (compare brackets). *Dmrt3*⁺ cells overlap with the dl4/dl5/dl6 marker *Lbx1*. **e**, Double immunolabelling with *Dmrt3* (arrowhead) and *Wt1* (double arrow) show a partial overlap (arrow). **f**, *Dmrt3*⁺ interneurons (arrows) co-labelled with *Viaat* mRNA (green) but not with *Vglut2* mRNA (green). **g**, Schematic of trans-synaptic muscle tracing of *Dmrt3* neurons in the spinal cord ($n = 6$, ipsilateral; $n = 5$, contralateral). **h**, Double immunolabelling of *Dmrt3* and green fluorescent protein (PRV152) show that both ipsi- and contralateral premotor interneurons overlap with *Dmrt3*⁺ cells (arrows). **i**, Quantification of *Brn3a*/*Lbx1*-positive neurons (control $n_{\text{section}} = 16$, *Dmrt3*^{-/-} $n_{\text{section}} = 21$) and of *Lbx1*/*Pax2*-positive neurons (control $n_{\text{section}} = 11$, *Dmrt3*^{-/-} $n_{\text{section}} = 19$). **j**, Immunolabelling of *Wt1*⁺ cells (red) in spinal cord sections from control and *Dmrt3*^{-/-} E15.5 embryos. **k**, Quantification demonstrated that loss of *Dmrt3* leads to an expanded *Wt1*⁺ cell subpopulation (control $n = 43$, *Dmrt3*^{+/-} $n = 36$, *Dmrt3*^{-/-} $n = 46$, *** $P < 0.0001$). **l**, Schematic illustration of fate change in the *Dmrt3* dl6 population of neurons. Mean $\pm$ s.e.m. Scale bars: 400 μ m (**a**), 70 μ m (**b**, **d**, **j**), 50 μ m (**e**, **f**, **h**).

Expression levels between mutant and wild-type homozygotes were similar and *DMRT3* mRNA was found in a small population of neurons located in the ventral horn and around the central canal in both wild-type and mutant horses (Supplementary Fig. 1c–e). Furthermore,

transfection experiments and an electrophoretic mobility shift assay indicated that the mutant *Dmrt3* protein maintain its cellular localization and DNA-binding profile (Supplementary Fig. 1f, g). It may therefore be a dominant negative form with normal DNA binding but defective protein interactions.

The remarkable association between the *DMRT3* nonsense mutation and gaitedness across horse breeds, combined with the demonstration that mouse *Dmrt3* is required for normal development of a coordinated locomotor network in the spinal cord, allow us to conclude that *DMRT3_Ser301STOP* is a causative mutation affecting the pattern of locomotion in horses. The horse phenotype indicates that *Dmrt3* neurons not only have a critical role for left/right coordination but also for coordinating the movement of the fore- and hindlegs. The mutation facilitates lateral gaits, ambling and pace, and inhibits the transition from trot or pace to gallop. Homozygosity for the mutation is required, but not sufficient for pacing, as many Standardbred trotters and some Icelandic horses that are homozygous mutant do not pace. In mice, a complete loss of *Dmrt3* on one allele does not lead to any detectable phenotype, whereas in Icelandic horses, heterozygosity for the *DMRT3_Ser301STOP* mutation promotes tölt, supporting our hypothesis that the mutant protein in horses acts as a dominant negative form. *Dmrt3* neurons are present in the horse and mouse spinal cord, and in the mouse, they develop into premotor inhibitory interneurons projecting ipsi- and contralaterally. Inhibitory commissural connections have been suggested as major constituents of left-right phasing during locomotion^{23–25}, and in cat, such interneurons have been implicated in mediation of the crossed reflexes and in the selection of different motor patterns^{26,27}. Thus, *Dmrt3* neurons have a character and position in spinal cord circuitry that concurs with gait coordination.

METHODS SUMMARY

A summary of the methods can be found in the Supplementary Information and includes detailed information on study populations, genotyping methods and genome-wide association analysis, genome resequencing and calling of genetic variants, *Dmrt3*-null mice, immunohistochemistry, *in situ* hybridization of mouse and horse tissue, spinal cord and muscle tracing, extracellular physiology, behaviour recordings and statistical analyses, expression analysis using mouse and horse tissue, transfection experiments and electrophoretic mobility shift assays.

Received 18 April; accepted 5 July 2012.

- Grillner, S. Biological pattern generation: the cellular and computational logic of networks in motion. *Neuron* **52**, 751–766 (2006).
- Kullander, K. Genetics moving to neuronal networks. *Trends Neurosci.* **28**, 239–247 (2005).
- Albertsdóttir, E., Eriksson, S., Sigurdsson, A. & Arnason, T. Genetic analysis of 'breeding field test status' in Icelandic horses. *J. Anim. Breed. Genet.* **128**, 124–132 (2011).
- Hong, C. S., Park, B. Y. & Saint-Jeannet, J. P. The function of *Dmrt* genes in vertebrate development: it is not just about sex. *Dev. Biol.* **310**, 1–9 (2007).
- Ahituv, N. *et al.* Deletion of ultraconserved elements yields viable mice. *PLoS Biol.* **5**, e234 (2007).
- Gallarda, B. W., Sharpee, T. O., Pfaff, S. L. & Alaynick, W. A. Defining rhythmic locomotor burst patterns using a continuous wavelet transform. *Ann. NY Acad. Sci.* **1198**, 133–139 (2010).
- Mor, Y. & Lev-Tov, A. Analysis of rhythmic patterns produced by spinal neural networks. *J. Neurophysiol.* **98**, 2807–2817 (2007).
- Kullander, K. *et al.* Role of EphA4 and EphrinB3 in local neuronal circuits that control walking. *Science* **299**, 1889–1892 (2003).
- Alaynick, W. A., Jessell, T. M. & Pfaff, S. L. SnapShot: spinal cord development. *Cell* **146**, 178e1 (2011).
- Jostes, B., Walther, C. & Gruss, P. The murine paired box gene, *Pax7*, is expressed specifically during the development of the nervous and muscular system. *Mech. Dev.* **33**, 27–37 (1990).

- Burrill, J. D., Moran, L., Goulding, M. D. & Saueressig, H. PAX2 is expressed in multiple spinal cord interneurons, including a population of EN1⁺ interneurons that require PAX6 for their development. *Development* **124**, 4493–4503 (1997).
- Moran-Rivard, L. *et al.* *Evx1* is a postmitotic determinant of V0 interneuron identity in the spinal cord. *Neuron* **29**, 385–399 (2001).
- Müller, T. *et al.* The homeodomain factor *lhx1* distinguishes two major programs of neuronal differentiation in the dorsal spinal cord. *Neuron* **34**, 551–562 (2002).
- Gross, M. K., Dottori, M. & Goulding, M. *Lbx1* specifies somatosensory association interneurons in the dorsal spinal cord. *Neuron* **34**, 535–549 (2002).
- Goulding, M. Circuits controlling vertebrate locomotion: moving in a new direction. *Nature Rev. Neurosci.* **10**, 507–518 (2009).
- Gezelius, H., Wallen-Mackenzie, A., Enjin, A., Lagerstrom, M. & Kullander, K. Role of glutamate in locomotor rhythm generating neuronal circuitry. *J. Physiol. Paris* **100**, 297–303 (2006).
- Rabe, N., Gezelius, H., Vallstedt, A., Memic, F. & Kullander, K. Netrin-1-dependent spinal interneuron subtypes are required for the formation of left-right alternating locomotor circuitry. *J. Neurosci.* **29**, 15642–15649 (2009).
- Jovanovic, K., Pastor, A. M. & O'Donovan, M. J. The use of PRV-Bartha to define premotor inputs to lumbar motoneurons in the neonatal spinal cord of the mouse. *PLoS ONE* **5**, e11743 (2010).
- Lanuza, G. M., Gosgnach, S., Pierani, A., Jessell, T. M. & Goulding, M. Genetic identification of spinal interneurons that coordinate left-right locomotor activity necessary for walking movements. *Neuron* **42**, 375–386 (2004).
- Pierani, A. *et al.* Control of interneuron fate in the developing spinal cord by the progenitor homeodomain protein *Dbx1*. *Neuron* **29**, 367–384 (2001).
- Vallstedt, A. *et al.* Different levels of repressor activity assign redundant and specific roles to *Nkx6* genes in motor neuron and interneuron specification. *Neuron* **31**, 743–755 (2001).
- Culbertson, M. R. & Leeds, P. F. Looking at mRNA decay pathways through the window of molecular evolution. *Curr. Opin. Genet. Dev.* **13**, 207–214 (2003).
- Cowley, K. C. & Schmidt, B. J. Effects of inhibitory amino acid antagonists on reciprocal inhibitory interactions during rhythmic motor activity in the *in vitro* neonatal rat spinal cord. *J. Neurophysiol.* **74**, 1109–1117 (1995).
- Grillner, S. & Wallen, P. Does the central pattern generation for locomotion in lamprey depend on glycine inhibition? *Acta Physiol. Scand.* **110**, 103–105 (1980).
- Jankowska, E. & Noga, B. R. Contralaterally projecting lamina VIII interneurons in middle lumbar segments in the cat. *Brain Res.* **535**, 327–330 (1990).
- Harrison, P. J., Jankowska, E. & Zytnicki, D. Lamina VIII interneurons interposed in crossed reflex pathways in the cat. *J. Physiol. (Lond.)* **371**, 147–166 (1986).
- Jankowska, E., Edgley, S. A., Krutki, P. & Hammar, I. Functional differentiation and organization of feline midlumbar commissural interneurons. *J. Physiol. (Lond.)* **565**, 645–658 (2005).

Supplementary Information is available in the online version of the paper.

Acknowledgements Thanks to S. Mikulovic and E. Restrepo for valuable input, C. Birchmeier for *Lbx1* antibody, L. Enquist and J. Martin for PRV152, S. Ewart for horse samples, and B. Ågerup for access to race horses. The work was supported by grants from the Swedish Foundation for Strategic Research, the Swedish Research Council Formas (221-2009-1631), Swedish Research Council Medicine and Health (2007-3630/4479, 2010-4394), Swedish Society for Medical Research (H.W.), National Institute of Child Health & Human Development R01HD059862 (N.A.), and the Swedish Brain Foundation. Sequencing was performed by the SNP&SEQ Technology Platform, supported by Uppsala University and Hospital, SciLife Lab – Uppsala and the Swedish Research Council (80576801 and 70374401). Computer resources were supplied by UPPMAX. K.K. is a Royal Swedish Academy of Sciences Research Fellow supported by a grant from the Knut and Alice Wallenberg Foundation.

Author Contributions L.S.A., S.M., G.L. and L.W. collected the horse material and/or performed the genome-wide association analysis. L.S.A., D.S., M.L., G.H. and L.A. planned, designed, performed and/or analysed horse experiments. M.L., F.M., H.W., K.P., A.V. and K.K. planned, designed performed and/or analysed mouse experiments. C.-J.R. performed bioinformatic analysis. T.A. analysed horse performance data. N.A., F.I., J.L.P., M.E.M., J.R.M. and G.C. contributed with materials. L.R. recorded horse gaits. L.A. led positional cloning and characterisation of horse *DMRT3*. K.K. led the mouse studies. K.K. and L.A. wrote the paper with contributions from all authors.

Author Information The Illumina reads have been submitted to the short reads archive (<http://www.ncbi.nlm.nih.gov/sra>); the accession number for the study is SRP012260 and accession numbers for individual data are: four-gaited horse, SRS309533; five-gaited horse, SRS309532. Sanger sequencing data have been submitted to GenBank (accession numbers JQ922365–JQ922395). Reprints and permissions information is available at www.nature.com/reprints. This paper is distributed under the terms of the Creative Commons Attribution-Non-Commercial-Share Alike licence, and the online version of the paper is freely available to all readers. The authors declare competing financial interests: details are available in the online version of the paper. Readers are welcome to comment on the online version of the paper. Correspondence and requests for materials should be addressed to L.A. (leif.andersson@imbim.uu.se).